Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRIFT: Dual antiplatelet therapy vs rivaroxaban after left atrial appendage closure in atrial fibrillation
2017-001567-20Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban, aspirin and clopidogrel in Atrial fibrillation (AFib) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2017; status: completed.
02
Drugs
rivaroxabanaspirinclopidogrel
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2017-001567-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001567-20.